TailorMed Gets Majority Investment From GrowthCurve
Medication access technology firm TailorMed secures majority private equity backing from New York-based GrowthCurve Capital to scale its software portfolio.
Updated on Nov. 3, 2026 in Healthcare
Live Poll
Do you think private equity firms improve how affordable prescription medicines are?
TailorMed, a medication access and financial assistance technology company, has secured a majority private equity investment from GrowthCurve Capital, a New York firm focused on middle-market technology enterprises. The investment is intended to scale TailorMed's AI-enabled software portfolio and expand its distribution.
Why it matters
The investment targets high financial toxicity and therapy drop-off among oncology, rare disease, and chronic specialty patients, where expensive out-of-pocket costs drive prescription abandonment. Backing for platforms that connect clinical, pharmacy, and assistance workflows could shape how medication access tools reach the U.S. healthcare system.
TailorMed reports reaching more than 75 million patients and unlocking over $7.4 billion in financial assistance since 2020, drawing on a network of 950 hospitals, 4,700 outpatient clinics and 3,100 pharmacies. The company has not disclosed the size of the majority stake or the investment amount.
The players
GrowthCurve Capital
A New York-based private equity firm that focuses on accelerating middle-market technology enterprises.
TailorMed
A medication access and financial assistance technology company whose platform connects hospitals, clinics, pharmacies and life sciences manufacturers.
The details
TailorMed's platform integrates directly into clinical and pharmacy management workflows, bridging clinical EHR charting, pharmacy dispensing queues and manufacturer affordability programs. The company was founded in 2016 by Srulik Dvorsky and Adam Siton.
Timeline
2016: TailorMed is founded by Srulik Dvorsky and Adam Siton.
2020: TailorMed begins reporting its patient and financial assistance totals.
November 2, 2026: The majority investment from GrowthCurve Capital is announced.
Market Landscape
The investment places TailorMed's clinical-pharmacy-assistance integration model within a growing market for software that addresses financial toxicity in specialty care. It positions the company to expand across hospital systems, ambulatory clinics, retail and specialty pharmacies, and life sciences manufacturers.
Patients facing high out-of-pocket costs for specialty medications may see their access and assistance options expand as platforms like TailorMed scale across hospitals and pharmacies. The practical effect for individuals depends on which providers and manufacturer programs adopt the platform.
The takeaway
Patients prescribed costly specialty medications can ask their providers and pharmacies whether manufacturer or nonprofit financial assistance programs are available before abandoning a prescription. Tools that coordinate these programs are becoming more integrated into everyday clinical workflows.
Further reading
Explore more on Healthcare coverage across the United States.
Source note: This article includes information reported by Hitconsultant.
Live Poll
Do you think private equity firms improve how affordable prescription medicines are?
